Professional Documents
Culture Documents
Abstract
Introduction
The monoclonal antibodies (moAb) panitumumab and cetux-
Table 2. Univariate analysis of the association between clinical and pathologic characteristics, mutations of PIK3CA, and loss
of PTEN in 110 mCRC patients treated with anti-EGFR monoclonal antibodies panitumumab or cetuximab
WT (%) Mut (%) P WT (%) Mut (%) P WT (%) Mut (%) P Normal (%) Loss (%) P
Sex
Men 58 (81.7) 13 (18.3) 0.080 55 (77.5) 16 (22.5) 0.046 43 (60.6) 28 (39.4) 0.684 31 (63.3) 18 (36.7) 0.643
Women 37 (94.8) 2 (5.13) 22 (57.9) 16 (42.1) 21 (55.3) 17 (44.7) 18 (56.2) 14 (43.8)
Age (y)
V65 54 (87.1) 8 (12.9) 1.000 45 (72.6) 17 (27.4) 0.621 38 (61.3) 24 (38.7) 0.664 25 (55.6) 20 (44.4) 0.548
66–74 24 (85.7) 4 (14.3) 17 (63.0) 10 (37.0) 14 (51.8) 13 (48.2) 13 (61.9) 8 (38.1)
z75 17 (89.5) 2 (10.5) 14 (73.7) 5 (26.3) 12 (63.2) 7 (36.8) 10 (71.4) 4 (28.6)
Site of T*
Colon 48 (69.6) 21 (30.4) 0.319 62 (89.9) 7 (10.1) 0.157 41 (59.4) 28 (40.6) 0.153 30 (58.8) 21 (41.2) 0.715
Sigma-rectum 10 (90.9) 1 (9.1) 10 (90.9) 1 (9.1) 9 (81.8) 2 (18.2) 5 (71.4) 2 (28.6)
Rectum 18 (66.7) 9 (33.3) 21 (75.0) 7 (25.0) 13 (48.1) 14 (51.9) 14 (66.7) 7 (33.3)
Cutaneous rash
0–1 49 (67.1) 24 (32.9) 0.494 62 (83.8) 12 (16.2) 0.545 38 (52.0) 35 (48.0) 0.136 32 (55.2) 26 (44.8) 0.064
2–3 24 (75.0) 8 (25.0) 29 (90.6) 3 (9.4) 22 (68.7) 10 (31.3) 16 (80.0) 4 (20.0)
Table 3.
A. Univariate analysis of the association of PIK3CA mutations, KRAS mutations, and PTEN protein expression with clinical outcome of
mCRC patients treated with the anti-EGFR monoclonal antibodies cetuximab or panitumumab. Responders are patients who achieved
PR; nonresponders are PD and SD (RECIST)
WT (%) Mut (%) P WT (%) Mut (%) P WT (%) Mut (%) P Normal (%) Loss (%) P
Objective response
Responders 22 (100) 0 (0) 0.038 20 (90.9) 2 (9.1) 0.019 20 (90.9) 2 (9.1) 0.001 17 (94.4) 1 (5.6) 0.001
Nonresponders 73 (82.9) 15 (17.1) 57 (65.5) 30 (34.5) 44 (50.6) 43 (49.4) 32 (50.8) 31 (42.2)
B. Multivariate logistic regression of the association between PIK3CA mutations, KRAS mutations, and PTEN protein expression and objective
response (any single P value is adjusted with respect to other regressors)
C. Multivariate Cox survival analysis of the association between KRAS mutations, PIK3CA mutations, and/or PTEN loss and risk of progression
In univariate analysis, PIK3CA mutations were significantly were analyzed, the statistical association between PIK3CA muta-
associated with lack of response to panitumumab or cetuximab, tions with lack of response to panitumumab or cetuximab was
with none of the mutated patients achieving objective tumor confirmed (P = 0.016). In bivariate analysis, PIK3CA mutations and
response (P = 0.038). The same negative association was observed KRAS mutations were simultaneously significant (P = 0.0234 and
for KRAS mutations (9.1% of mutations among responders versus 0.0125, respectively); in multivariate logistic regression, an inde-
34.5% among non responders; P = 0.019) and was confirmed pendent effect of PIK3CA mutations, KRAS mutations, and PTEN
when at least a mutation of either KRAS or PIK3CA was consi- protein expression was also confirmed (P = 0.0337, 0.0029, and
dered (P = 0.001; Table 3A). When only KRAS wild-type tumors 0.0012, respectively; Table 3B). Our data indicate that similarly to
Figure 1. Kaplan-Meier cumulative PFS on the basis of PIK3CA and KRAS mutational status and PTEN protein expression in mCRC patients treated with panitumumab
and cetuximab. A, PIK3CA wild-type (wt) versus mutated; B, KRAS wild-type versus mutated; C, either PIK3CA or KRAS mutated versus both wild-type; D, PTEN
loss of expression versus normal; E, either PIK3CA mutated or loss of PTEN versus both normal; F, PIK3CA wild-type versus mutated in KRAS wild-type only patients.
Figure 2. Kaplan-Meier cumulative OS according to PIK3CA and KRAS mutational status and PTEN protein expression. A, PIK3CA wild-type versus mutated; B,
KRAS wild-type versus mutated; C, either PIK3CA or KRAS mutated versus both wild-type; D , PTEN loss of expression versus normal; E, either PIK3CA mutated
or loss of PTEN versus both normal; F , PIK3CA wild-type versus mutated in KRAS wild-type only patients.
KRAS, PIK3CA wild-type status represents a necessary but not harboring PIK3CA mutations had a worse clinical outcome in
sufficient condition to reach objective response. Assessment of terms of PFS, compared with wild-type tumors (P = 0.0035;
PIK3CA mutations therefore represents an independent factor Fig. 1A). Patients with KRAS mutations had a trend toward a
to predict clinical outcome among KRAS wild-type patients. decreased PFS (P = 0.0815; Fig. 1B). Shorter PFS was also detected
PIK3CA mutations and PTEN loss are negatively associated in patients harboring at least a mutation of either KRAS or PIK3CA
with survival in mCRCs patients treated with panitumumab or (P = 0.0032; Fig. 1C). PTEN loss was similarly associated with
cetuximab. Analysis of survival showed that patients with tumors shorter PFS (P = 0.0681) that reached statistical significance if